Impressive preclinical studies have prompted Boehringer Ingelheim GMBHto license OSE Immunotherapeutics SA' s novel checkpoint inhibitor antibody that's designed to treat advanced solid tumors, in a deal that could generate up €1.1bn for the French biotech.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?